depression

News

Volunteers with schizophrenia, bipolar, and depression will take part in an NHS study that will use genetic and health data to find new therapies.

News

Armed with new data, Compass wants to talk to the FDA about filing its psilocybin therapy COMP360 for approval in treatment-resistant depression.

News

Helus' psychedelic derived from ayahuasca, a brew used in shamanistic rituals in South America, has shown promise as a treatment for depression.

R&D

At the Sachs Neuroscience Forum just before the start of JPM 2026 in San Francisco, pharmaphorum spoke with Amit Etkin, CEO of Alto Neuroscience.

News

Flow Neuroscience has secured FDA approval for FL-100, the first at-home brain stimulation device for major depressive disorder.

News

Johnson & Johnson has clinched an FDA approval for Caplyta in depression, satisfying a major driver for its $14.6bn takeover of ICT this year.